Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Texas-based biotech PharmaFrontiers has formed an alliance with contract research firm INC Research to develop multiple sclerosis therapies.
Subscribe to our email newsletter
PharmaFrontiers has a history of developing autologous cellular therapies for the treatment of multiple sclerosis and is currently moving into phase II clinical trials with its novel therapy Tovaxin, a treatment based on its proprietary T-cell therapy (T cell vaccination) technologies.
PharmaFrontiers chose INC Research to manage its multiple sclerosis development program based on the company’s longstanding history of developing central nervous system therapies. INC Research, a global contract research organization, specializes in CNS, oncology, and pediatric clinical research.
David McWilliams, CEO of PharmaFrontiers said: “We have selected INC Research as they are recognized leaders in the field of CNS research. Their scientific, regulatory, and clinical teams have a substantial depth of multiple sclerosis expertise and drug development experience that will be instrumental in ensuring that we continue to hit our critical milestones. We are pleased to have INC Research as our CRO partner.”